CENTENE CORPORATION (CNC) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.13%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.13% | Share-based compensation / revenue. Period ending 2026-06-30. $236.00M ÷ $178.66B × 100 ≈ 0.13% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 178.66B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 236.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -5.64B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $178.66B | $236.00M | $-5.64B | (m) | (m) | 0.13% | (m) | (m) |
| 2026-03-31 | (m) | $176.75B | $212.00M | $-7.30B | (m) | (m) | 0.12% | (m) | (m) |
| 2025-12-31 | (m) | $174.58B | $204.00M | $-7.62B | (m) | (m) | 0.12% | (m) | (m) |
| 2025-09-30 | (m) | $166.15B | $177.00M | $-5.70B | (m) | (m) | 0.11% | (m) | (m) |
| 2025-06-30 | (m) | $158.15B | $174.00M | $1.92B | (m) | (m) | 0.11% | (m) | (m) |
| 2025-03-31 | (m) | $151.66B | $201.00M | $3.60B | (m) | (m) | 0.13% | (m) | (m) |
| 2024-12-31 | (m) | $145.50B | $212.00M | $3.17B | (m) | (m) | 0.15% | (m) | (m) |
| 2024-09-30 | (m) | $144.55B | $230.00M | $2.81B | (m) | (m) | 0.16% | (m) | (m) |
| 2024-06-30 | (m) | $142.62B | $231.00M | $2.88B | (m) | (m) | 0.16% | (m) | (m) |
| 2024-03-31 | (m) | $141.48B | $225.00M | $2.82B | $723.00M | (m) | 0.16% | 3.90× | Reported |
| 2023-12-31 | (m) | $140.09B | $216.00M | $2.93B | $725.00M | (m) | 0.15% | 4.04× | Reported |
| 2023-09-30 | (m) | $138.31B | $221.00M | $2.84B | $716.00M | (m) | 0.16% | 3.97× | Reported |
| 2023-06-30 | (m) | $137.07B | $222.00M | $2.58B | $704.00M | (m) | 0.16% | 3.67× | Reported |
| 2023-03-31 | (m) | $136.20B | $225.00M | $1.28B | $685.00M | (m) | 0.17% | 1.87× | Reported |
| 2022-12-31 | (m) | $135.48B | $234.00M | $1.32B | $665.00M | (m) | 0.17% | 1.98× | Reported |
| 2022-09-30 | (m) | $132.42B | $256.00M | $2.20B | $653.00M | (m) | 0.19% | 3.37× | Reported |
| 2022-06-30 | (m) | $129.21B | $245.00M | $2.27B | $654.00M | (m) | 0.19% | 3.47× | Reported |
| 2022-03-31 | (m) | $124.10B | $222.00M | $1.98B | $655.00M | (m) | 0.18% | 3.03× | Reported |
| 2021-12-31 | (m) | $117.98B | $203.00M | $1.78B | $665.00M | (m) | 0.17% | 2.68× | Reported |
| 2021-09-30 | (m) | $113.94B | $190.00M | $1.20B | $680.00M | (m) | 0.17% | 1.76× | Reported |
| 2021-06-30 | (m) | $110.88B | $204.00M | $1.51B | $694.00M | (m) | 0.18% | 2.18× | Reported |
| 2021-03-31 | (m) | $107.74B | $215.00M | $3.95B | $718.00M | (m) | 0.20% | 5.50× | Reported |
| 2020-12-31 | (m) | $103.80B | $281.00M | $3.08B | $728.00M | (m) | 0.27% | 4.23× | Reported |
| 2020-09-30 | (m) | $95.37B | $289.00M | $3.34B | $664.00M | (m) | 0.30% | 5.04× | Reported |
| 2020-06-30 | (m) | $86.12B | $269.00M | $2.66B | $579.00M | (m) | 0.31% | 4.59× | Reported |
| 2020-03-31 | (m) | $77.70B | $256.00M | $1.28B | $493.00M | (m) | 0.33% | 2.60× | Reported |
| 2019-12-31 | (m) | $70.36B | $177.00M | $1.78B | $412.00M | (m) | 0.25% | 4.32× | Reported |
| 2019-09-30 | (m) | $68.00B | $146.00M | $1.89B | $397.00M | (m) | 0.21% | 4.77× | Reported |
| 2019-06-30 | (m) | $65.14B | $150.00M | $1.76B | $395.00M | (m) | 0.23% | 4.45× | Reported |
| 2019-03-31 | (m) | $60.72B | $150.00M | $1.60B | $374.00M | (m) | 0.25% | 4.29× | Reported |
| 2018-12-31 | (m) | $56.44B | $145.00M | $1.46B | $343.00M | (m) | 0.26% | 4.25× | Reported |
| 2018-09-30 | (m) | $55.14B | $141.00M | $1.25B | $311.00M | (m) | 0.26% | 4.02× | Reported |
| 2018-06-30 | (m) | $51.21B | $140.00M | $1.55B | $279.00M | (m) | 0.27% | 5.56× | Reported |
| 2018-03-31 | (m) | $49.85B | $136.00M | $1.50B | $261.00M | (m) | 0.27% | 5.74× | Reported |
| 2017-12-31 | (m) | $48.38B | $135.00M | $1.20B | $255.00M | (m) | 0.28% | 4.70× | Reported |
| 2017-09-30 | (m) | $47.49B | $135.00M | $1.54B | $264.00M | (m) | 0.28% | 5.83× | Reported |
| 2017-06-30 | (m) | $46.44B | $127.00M | $1.54B | $256.00M | (m) | 0.27% | 6.02× | Reported |
| 2017-03-31 | (m) | $45.38B | $129.00M | $1.48B | $246.00M | (m) | 0.28% | 6.02× | Reported |
| 2016-12-31 | (m) | $40.61B | $148.00M | $1.26B | $217.00M | (m) | 0.36% | 5.81× | Reported |
| 2016-09-30 | (m) | $35.00B | $135.00M | $959.00M | $153.00M | (m) | 0.39% | 6.27× | Reported |
| 2016-06-30 | (m) | $29.97B | $121.00M | $800.00M | $107.00M | (m) | 0.40% | 7.48× | Reported |
| 2016-03-31 | (m) | $24.58B | $106.00M | $596.00M | $66.00M | (m) | 0.43% | 9.03× | Reported |
| 2015-12-31 | (m) | $22.76B | $71.00M | $705.00M | $43.00M | (m) | 0.31% | 16.40× | Reported |
| 2015-09-30 | (m) | $21.18B | $61.00M | $678.00M | $42.00M | (m) | 0.29% | 16.14× | Reported |
| 2015-06-30 | (m) | $19.71B | $58.00M | $603.00M | $40.00M | (m) | 0.29% | 15.07× | Reported |
| 2015-03-31 | (m) | $18.23B | $53.00M | $523.00M | $38.00M | (m) | 0.29% | 13.76× | Reported |
| 2014-12-31 | (m) | $16.56B | $48.00M | $464.00M | $35.00M | (m) | 0.29% | 13.26× | Reported |
| 2014-09-30 | (m) | $14.77B | $44.02M | $355.73M | $31.61M | (m) | 0.30% | 11.26× | Reported |
| 2014-06-30 | (m) | $13.21B | $42.45M | $331.79M | $28.93M | (m) | 0.32% | 11.47× | Reported |
| 2014-03-31 | (m) | $11.80B | $39.58M | $307.85M | $27.36M | (m) | 0.34% | 11.25× | Reported |
| 2013-12-31 | (m) | $10.86B | $36.66M | $277.42M | $26.96M | (m) | 0.34% | 10.29× | Reported |
| 2013-09-30 | (m) | $10.57B | $34.17M | $202.43M | $26.33M | (m) | 0.32% | 7.69× | Reported |
| 2013-06-30 | (m) | $10.22B | $30.29M | $92.56M | $24.58M | (m) | 0.30% | 3.77× | Reported |
| 2013-03-31 | (m) | $9.60B | $27.33M | $-21.21M | $22.29M | (m) | 0.28% | -0.95× | Reported |
| 2012-12-31 | (m) | $8.67B | $25.33M | $-27.12M | $20.46M | (m) | 0.29% | -1.33× | Reported |
| 2012-09-30 | (m) | $7.78B | $23.32M | $7.19M | $19.19M | (m) | 0.30% | 0.37× | Reported |
| 2012-06-30 | (m) | $6.63B | $21.32M | $83.38M | $18.91M | (m) | 0.32% | 4.41× | Reported |
| 2012-03-31 | (m) | $5.84B | $20.15M | $185.43M | $19.42M | (m) | 0.35% | 9.55× | Reported |
| 2011-12-31 | (m) | $5.34B | $18.17M | $190.32M | $20.32M | (m) | 0.34% | 9.37× | Reported |
| 2011-09-30 | (m) | $5.01B | $16.91M | $188.45M | $20.98M | (m) | 0.34% | 8.98× | Reported |
| 2011-06-30 | (m) | $4.83B | $15.82M | $180.15M | $21.26M | (m) | 0.33% | 8.47× | Reported |
| 2011-03-31 | (m) | $4.60B | $14.81M | $166.56M | $19.87M | (m) | 0.32% | 8.38× | Reported |
| 2010-12-31 | (m) | $4.45B | $13.87M | $157.07M | $17.99M | (m) | 0.31% | 8.73× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $4.10B | $14.63M | $138.13M | $16.32M | (m) | 0.36% | 8.47× | Reported |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $3.36B | $15.33M | $131.56M | $16.67M | (m) | 0.46% | 7.89× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HUMANA INC (HUM) | United States | $45.651B | 18.44 |
| MOLINA HEALTHCARE, INC. (MOH) | United States | $10.091B | -1,697.50 |
| Alignment Healthcare, Inc. (ALHC) | United States | $1.593B | 121.28 |
| TRUPANION, INC. (TRUP) | United States | $0.984B | |
| Cigna Group (CI) | United States | $70.160B | 10.44 |
| Elevance Health, Inc. (ELV) | United States | $86.364B | 16.90 |
| UNITEDHEALTH GROUP INC (UNH) | United States | $336.652B | 26.62 |